Transplantable bioartificial pancreas devices: current status and future prospects

Area of Science:

• Biomaterials Science
• Regenerative Medicine
• Transplantation Immunology

Background:

• Islet transplantation is a vital therapy for type 1 diabetes, but limited by lifelong immunosuppression needs and donor organ scarcity.
• Current transplant candidates are restricted to patients with severe, unstable diabetes unresponsive to insulin therapy.
• Research is actively exploring solutions to broaden access to beta cell replacement therapy for more diabetes patients.

Purpose of the Study:

• To review current encapsulation technologies for pancreatic islet cell replacement therapy in type 1 diabetes.
• To highlight advancements and challenges in utilizing encapsulation to overcome transplantation barriers.

Main Methods:

• Exploration of alginate-based macro- and microcapsule configurations for islet encapsulation.
• Assessment of encapsulation's potential to negate the requirement for immunosuppressive agents.
• Consideration of expanding the donor pool to include animal tissues and novel cell sources.

Main Results:

• Encapsulation may protect islet grafts, potentially removing the need for immunosuppression.
• This approach could broaden the scope of donor tissues and cell types for transplantation.
• Significant challenges remain, including graft oxygenation, immune protection, inflammatory responses, material biocompatibility, and optimal transplantation sites.

Conclusions:

• Renewed interest in encapsulation is driven by advances in xenotransplantation and stem cell-derived beta cells.
• Encapsulation technologies represent a key area of development for cell replacement therapy in type 1 diabetes.
• Further research is needed to address existing challenges for successful clinical translation.